Cargando…
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab 140 mg subcutaneously every 2 weeks. Trea...
Autores principales: | Fogacci, Federica, Borghi, Claudio, Di Micoli, Antonio, Cicero, Arrigo F. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468156/ http://dx.doi.org/10.3390/medicina57090857 |
Ejemplares similares
-
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021) -
Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia
por: Cicero, Arrigo F. G., et al.
Publicado: (2022) -
Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015) -
Noninvasive instrumental evaluation of coenzyme Q(10)
phytosome on endothelial reactivity in healthy nonsmoking young volunteers: A double‐blind, randomized, placebo‐controlled crossover clinical trial
por: Cicero, Arrigo F. G., et al.
Publicado: (2022) -
Purine Metabolism Dysfunctions: Experimental Methods of Detection and Diagnostic Potential
por: Cicero, Arrigo F. G., et al.
Publicado: (2023)